MaxCyte, Inc.
MaxCyte, Inc. is a biotechnology research company based in Rockville, Maryland, specializing in electroporation systems and various life sciences applications. Founded in 1999, the company supports partners in transforming human health through its ExPERT™ platform and a range of proprietary processing assemblies.
Company Overview
MaxCyte, Inc. is a biotechnology research company founded in 1999 and headquartered in Rockville, Maryland, USA. The company operates as a public entity and has a team size of 140 employees, classifying it as a medium-sized business. MaxCyte focuses on advancing human health through innovative technologies and solutions in the life sciences sector.
Electroporation Systems
MaxCyte offers a comprehensive range of electroporation systems designed for various applications and scales. The ExPERT™ platform includes four instruments: ATx™, STx™, GTx™, and VLx™. These systems are utilized in research and development across multiple specialties, including cancer research, immuno-oncology, and cell engineering. The systems facilitate processes such as transfection and gene editing.
Specialties
MaxCyte specializes in several key areas within biotechnology and life sciences. The company has expertise in cancer research, immunotherapy, and cell therapy, as well as vaccine development and protein production. Additionally, MaxCyte focuses on innovative approaches in gene therapy, CARMA, and cell engineering, contributing to advancements in human health.
Technical and Regulatory Support
MaxCyte provides technical and regulatory support to its partners, aiding them in transforming human health. This support is essential for the successful implementation of their electroporation systems and related processing assemblies. The company emphasizes collaboration and innovation in its approach to advancing biotechnology solutions.
Research Applications
MaxCyte's electroporation systems are utilized in various research applications, including studies involving T cells, NK cells, and bispecifics. The company's technology supports critical processes in cell engineering and gene editing, enabling researchers to explore new avenues in cancer treatment and immuno-oncology.